Literature DB >> 22819240

An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis.

Deborah A Williamson1, Indira Basu, James Bower, Joshua T Freeman, Gillian Henderson, Sally A Roberts.   

Abstract

Recent reports suggest that false-positive rifampicin resistance may be assigned by the Xpert MTB/RIF assay. We analysed 169 specimens using the MTB/RIF assay. Using culture as the gold standard, we found that the assay had 100% sensitivity and specificity for detecting M. tuberculosis. However, we found that the assay incorrectly assigned rifampicin resistance in 4/13 (31%) of cases.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22819240     DOI： 10.1016/j.diagmicrobio.2012.06.013

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  38 in total

1.  To build better tuberculosis diagnostics, look for 'biosignatures'.

Authors:  Alan Dove
Journal:  Nat Med       Date:  2015-07       Impact factor: 53.440

2.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

3.  Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance.

Authors:  Akos Somoskovi; Vanessa Deggim; Diana Ciardo; Guido V Bloemberg
Journal:  J Clin Microbiol       Date:  2013-07-12       Impact factor: 5.948

4.  False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load.

Authors:  Oksana Ocheretina; Erin Byrt; Marie-Marcelle Mabou; Gertrude Royal-Mardi; Yves-Mary Merveille; Vanessa Rouzier; Daniel W Fitzgerald; Jean W Pape
Journal:  Diagn Microbiol Infect Dis       Date:  2016-01-15       Impact factor: 2.803

5.  Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 Culture System for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence.

Authors:  Eiman Mokaddas; Suhail Ahmad; Hanaa S Eldeen; Noura Al-Mutairi
Journal:  J Clin Microbiol       Date:  2015-01-21       Impact factor: 5.948

Review 6.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 7.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

8.  Unsuccessful Xpert® MTB/RIF results: the Nigerian experience.

Authors:  M Gidado; N Nwokoye; P Nwadike; P Ajiboye; R Eneogu; S Useni; J Onazi; A Lawanson; E Elom; A Tubi; J Kuye
Journal:  Public Health Action       Date:  2018-03-21

9.  Multiplex detection of extensively drug resistant tuberculosis using binary deoxyribozyme sensors.

Authors:  Hillary N Bengtson; Susanne Homolka; Stefan Niemann; Ana Júlia Reis; Pedro Eduardo da Silva; Yulia V Gerasimova; Dmitry M Kolpashchikov; Kyle H Rohde
Journal:  Biosens Bioelectron       Date:  2017-03-01       Impact factor: 10.618

Review 10.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.